Ulrich Costabel


Country: Germany


  1. Costabel U, Bonella F, Guzman J. Chronic hypersensitivity pneumonitis. Clin Chest Med. 2012;33:151-63 pubmed publisher
    ..Additional research is needed to understand why the disease develops only in a minority of exposed individuals and why cases of chronic HP may progress without further antigen exposure. ..
  2. Costabel U. The changing treatment landscape in idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24:65-8 pubmed publisher
    ..Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage. ..
  3. Nathan S, du Bois R, Albera C, Bradford W, Costabel U, Kartashov A, et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109:914-22 pubmed publisher
    ..These results confirm previous findings in an independent cohort of patients with IPF. ..
  4. Griese M, Zarbock R, Costabel U, Hildebrandt J, Theegarten D, Albert M, et al. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulm Med. 2015;15:87 pubmed publisher
    ..Treatment with whole lung lavages as well as stem cell transplant may be successful. ..
  5. request reprint
    Costabel U, Albera C, Bradford W, Hormel P, King T, Noble P, et al. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:198-205 pubmed
    ..FVC and survival outcomes in IPF patients newly treated with pirfenidone in RECAP were similar to those in the CAPACITY pirfenidone group. These data provide further evidence to support the use of pirfenidone in patients with IPF. ..
  6. Bonella F, Sixt S, Thomassen J, Schmidt M, Cai M, Mori T, et al. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis. Immunobiology. 2015;220:382-8 pubmed publisher
    ..05). The 20S proteasome is increased and active in BAL of patients with PAP. Extracellular proteasome may contribute to the alveolar degradation of accumulated proteins in PAP. ..
  7. Costabel U. Idiopathic pulmonary fibrosis: recent milestones in disease management. Eur Respir Rev. 2012;21:140 pubmed publisher
  8. Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, et al. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis. Respir Med. 2017;123:105-109 pubmed publisher
    ..37; p = 0.031; 95% confidence interval, 1.16-24.82). FAM13A gene polymorphism showed a significant association with the susceptibility to IPF, with severity of lung function impairment and with poor prognosis. ..